Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma

被引：20

作者：

Karabulut S. ^{[1
]}

Afsar Ç.U. ^{[2
]}

Karabulut M. ^{[3
]}

Alış H. ^{[3
]}

Kılıc L. ^{[1
]}

Çikot M. ^{[3
]}

Yasasever C.T. ^{[4
]}

Aykan N.F. ^{[1
]}

机构：

[1] Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul

[2] Department of Medical Oncology, Istanbul Education and Research Hospital, Istanbul

[3] Clinic of General Surgery, Istanbul Bakırköy Dr. Sadi Konuk Education and Research Hospital, Istanbul

[4] Department of Basic Oncology, Institute of Oncology, Istanbul University, Istanbul

来源：

Journal of Gastrointestinal Cancer | 2016年 / 47卷 / 1期

关键词：

Diagnostic; IL-17; Pancreatic adenocancer; Serum;

D O I：

10.1007/s12029-015-9787-z

中图分类号：

学科分类号：

摘要：

Background: Inflammatory cytokines modulate immune responses in the tumor microenvironment during progression. The role of interleukin (IL-17) in cancer is currently under debate. This study was conducted to investigate the serum levels of IL-17 in patients with pancreatic adenocarcinoma (PA) and the relationship with tumor progression and known prognostic parameters. Material and Methods: Thirty-five patients with PA were investigated. Serum samples were obtained on first admission before treatment and follow-up. Both serum IL-17 levels were determined using enzyme-linked immunosorbent assay (ELISA). Age- and sex-matched 35 healthy controls were included in the analysis. Results: The median age at diagnosis was 61 years, range 38–84 years; 21 (60 %) patients were men. The tumor was located in the head of pancreas in 24 (69 %) patients. The most common metastatic site was liver in 20 patients with metastasis (n = 18, 90 %). The median follow-up time was 24.0 weeks (range 1.0–191.0 weeks). At the end of the observation period, 12 (34 %) patients experienced disease progression and 23 patients (66 %) were dead. Forty-four percent of 18 metastatic patients who received palliative chemotherapy (CTx) were CTx-responsive. Median progression-free survival and overall survival of the whole group were 13.7 ± 2.3 weeks [95 % confidence interval (CI) = 9–18 weeks] and 48.0 ± 12.8 weeks (95 % CI = 23–73 weeks), respectively. The baseline serum IL-17 levels were significantly higher in patients with PA than in the control group (p = 0.001). Moreover, serum IL-17 levels were significantly higher in the patients with large pathologic tumor status and low albumin levels (p = 0.04 and p = 0.03, respectively). However, serum IL-17 assays had no prognostic roles on outcome. Conclusion: Although serum levels of IL-17 assays were found to be diagnostic value, no predictive and prognostic value was determined in PA patients. © 2015, Springer Science+Business Media New York.

引用

页码：47 / 54

页数：7

共 30 条

[1]

Siegel R.L., Miller K.D., Jemal A., Cancer statistics, 2015, CA Cancer J Clin, 65, (2015)

[2]

Jemal A., Bray F., Center M.M., Et al., Global cancer statistics, CA Cancer J Clin, 61, (2011)

[3]

Zhang J., Dhakal I., Ning B., Kesteloot H., Patterns and trends of pancreatic cancer mortality rates in Arkansas, 1969–2002: a comparison with the US population, Eur J Cancer Prev, 17, (2008)

[4]

Yao Z., Franslow W.C., Seldin M.F., Rousseau A.-M., Painter S.L., Comeau M.R., Et al., Herpes virus saimiri encodes a new cytokine IL-17 which binds to novel cytokine receptor, Immunity, 3, pp. 811-821, (1995)

[5]

Shin H.C., Benbernou N., Esnault S., Guenounou M., Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway, Cytokine, 11, pp. 257-266, (1999)

[6]

Kinugasa T., Sakaguchi T., Gu X., Reinecker H.C., Claudins regulate the intestinal barrier in response to immune mediators, Gastroenterology, 118, pp. 1001-1011, (2000)

[7]

Schwartz S., Beaulieu J.F., Ruemmele F.M., Interleukin-17 is a potent immuno-modulator and regulator of normal human intestinal epithelial cell growth, Biochem Biophys Res Commun, 337, pp. 505-509, (2005)

[8]

Gnerlich J.L., Mitchem J.B., Weir J.S., Sankpal N.V., Kashiwagi H., Belt B.A., Et al., Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer, J Immunol, 185, 7, pp. 4063-4071, (2010)

[9]

Andoh A., Shimada M., Bamba S., Okuno T., Araki Y., Fujiyama Y., Et al., Extracellular signal-regulated kinases 1 and 2 participate in interleukin-17 plus tumor necrosis factor-alpha-induced stabilization of interleukin-6 mRNA in human pancreatic myofibroblasts, Biochim Biophys Acta, 1591, 1-3, pp. 69-74, (2002)

[10]

Bos P.D., Rudensky A.Y., Treg cells in cancer: a case of multiple personality disorder, Sci Transl Med, 4, 164, (2012)

← 1 2 3 →